Impact of call-to-balloon time on 30-day mortality in contemporary practice

Richard W Varcoe1, Tim C Clayton2, Huon H Gray3

  • 1Trent Cardiac Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Insights

Treatment delays in primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) increase mortality risk. Minimizing call-to-balloon (CTB) time is crucial, especially for high-risk patients, even within national reperfusion services.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Public Health

Background:

  • Previous studies on treatment delay in ST-elevation myocardial infarction (STEMI) often excluded patients receiving primary percutaneous coronary intervention (PPCI) within systematic reperfusion services.
  • Understanding the impact of call-to-balloon (CTB) time on outcomes in contemporary PPCI settings is essential.

Purpose of the Study:

  • To determine the association between call-to-balloon (CTB) time and 30-day mortality in patients undergoing primary percutaneous coronary intervention (PPCI) for STEMI.
  • To evaluate CTB time within a national reperfusion service framework.

Main Methods:

  • Analysis of 16,907 consecutive STEMI patients treated with PPCI in England and Wales in 2011, with CTB times ≤6 hours.
  • Statistical analysis to assess the independent association of CTB time with 30-day mortality, considering patient risk profiles.

Main Results:

  • Median CTB time was 111 minutes; 80.9% of patients were treated within 150 minutes.
  • Out-of-hours calls and inter-hospital transfers significantly increased CTB times.
  • CTB time was independently associated with 30-day mortality (HR 1.95 for CTB >180-240 min vs ≤90 min), with a greater impact in high-risk patients.

Conclusions:

  • Call-to-balloon (CTB) time remains a critical metric for assessing primary percutaneous coronary intervention (PPCI) service performance.
  • Efforts to minimize reperfusion delays are vital, even within established national PPCI services.
  • Patient risk stratification influences the impact of CTB time on mortality outcomes.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
405
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K
Cardiopulmonary Resuscitation I: Adult01:21

Cardiopulmonary Resuscitation I: Adult

Cardiopulmonary resuscitation, or CPR, is a life-saving emergency procedure performed when a person's heart has stopped beating or they are no longer breathing. The foundation of CPR is Basic Life Support (BLS), which focuses on the early recognition of cardiac arrest, the immediate start of high-quality chest compressions, and the timely use of an automated external defibrillator (AED).Assessing Responsiveness and Checking the Carotid PulseWhen approaching an unresponsive person, first ensure...
965
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511